Catalent-Repligen Merger ''Seems Unlikely,'' This Analyst Says Yesterday, Catalent Inc (NYSE: CTLT ) announced to acquire Metrics Contract Services for $475 million . Keybanc notes that the deal strengthens CTLT''s oral delivery portfolio and targets rapidly growing biologic applications. Metrics produces highly active pharmaceutical ingredients that are very difficult to produce but very potent in small doses. "After recent acquisitions and capacity expansion on the cell and gene therapy front, this acquisition will … Full story available on Benzinga.com